Evidence map›Paper›PMID 42024384›Full record

ArticleJAMA network open2026

A Prediction Model for Risk of Death in Kidney Transplant Recipients.

Charlotte Debiais-Deschamps, Marc Raynaud, Agathe Truchot, Yannis Lombardi, Gillian Divard, Vivek A Rudrapatna, Soufian Meziyerh, Jesper Kers, Danny van der Helm, Aiko P J de Vries and 21 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Charlotte Debiais-DeschampsParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Marc RaynaudParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Agathe TruchotParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Yannis LombardiParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Gillian DivardParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Vivek A RudrapatnaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco.
Soufian MeziyerhLeiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
Jesper KersLeiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
Danny van der HelmLeiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
Aiko P J de VriesLeiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
Juliette GueguenDepartment of Nephrology and Clinical Immunology, University Hospital of Tours, Tours, France.
Arnaud Del BelloDepartment of Nephrology and Organ Transplantation, Toulouse University Hospital, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1291, Toulouse Institute for Infectious and Inflammatory Diseases, University Paul Sabatier, Toulouse, France.
Elisabet Van LoonDepartment of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Antoine BouquegneauDivision of Nephrology, University Hospital Liège, University of Liège, Liège, Belgium.
Christophe LegendreKidney Transplant Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Xavier JouvenParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Adam MussellRenal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Brian McCauleyRenal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Sabrina EmmsRenal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Shristi MapchanRenal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Caroline C JadlowiecDepartment of Medicine, Mayo Clinic, Phoenix, Arizona.
Raymond L HeilmanDepartment of Medicine, Mayo Clinic, Phoenix, Arizona.
Devika DasDepartment of Medicine, Mayo Clinic, Phoenix, Arizona.
Nassim KamarDepartment of Nephrology and Organ Transplantation, Toulouse University Hospital, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1291, Toulouse Institute for Infectious and Inflammatory Diseases, University Paul Sabatier, Toulouse, France.
Dany AnglicheauKidney Transplant Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Kevin J FowlerThe Voice of The Patient Inc, St Louis, Missouri.
Maarten NaesensDepartment of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Carmen LefaucheurParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.
Olivier AubertKidney Transplant Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Peter P ReeseRenal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Alexandre LoupyParis Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France.

Funding

A data science framework for transforming electronic health records into real-world evidenceR00LM014099 · NLM · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Vivek Ashok Rudrapatna · 2025 to 2026
$498k
NLM NIH HHS R00 LM014099
6 · The paper itself

Abstract

Importance: Accurate prediction of patient mortality after kidney transplant is an unmet need. Objective: To develop and validate an integrative prediction model that predicts short- and long-term patient mortality for kidney recipients. Design, Setting, and Participants: This international cohort study included patients who underwent transplants between 2004 and 2023 from 14 academic medical centers from Europe and the US. The derivation cohort consisted of 1566 consecutive adult kidney recipients in a deeply phenotyped cohort prospectively recruited in 1 French center between 2004 and 2014. External validation cohorts consisted of 10 951 kidney recipients from 7 centers in France, 3 centers in Europe, and 3 centers in North America who underwent kidney transplants between 2006 and 2023. Data were analyzed from January 2023 to June 2025. Main Outcome and Measures: All-cause mortality was assessed, and 121 candidate prognostic factors, comprising demographics and clinical, biological, imaging, and immunological parameters, were collected. Results: Among 12 517 kidney transplant recipients, including 1566 in the derivation cohort (mean [SD] age, 50.05 [14.31] years; 942 male [60.15%]) and 10 951 in validation cohorts (mean [SD] age, 53.32 [13.97] years; 6766 male [61.78%]), 2486 patients (19.9%) died after a median (IQR) follow-up of 5.08 (2.97-7.00) years. Fourteen prognostic factors (including clinical, biological, and imaging risk factors) were independently associated with patient death (eg, patient age: hazard ratio per 1-year increase in age, 1.07 [95% CI, 1.06-1.08]; P < .001) and were combined into a risk prediction model (mBox). The model exhibited accurate calibration and discrimination in the derivation cohort, with C statistics of 0.82 (95% CI, 0.77-0.87) and 0.80 (95% CI, 0.78-0.82) at 1 and 10 years, respectively, after the transplant. Abbreviated models were developed and validated to ensure model generalizability. Performance of abbreviated models was confirmed in external validation cohorts from France (C statistic, 0.76 [95% CI, 0.73-0.78]), Europe (C statistic, 0.74 [95% CI, 0.72-0.76]), the US (C statistic, 0.74 [95% CI, 0.70-0.78]), the Greater Paris University Hospital database (C statistic, 0.79 [95% CI, 0.77-0.81]), and the University of California at San Francisco database (C statistic, 0.70 [95% CI, 0.65-0.74]). The model was also validated in a series of subpopulations (eg, women vs men: C statistic, 0.81 [95% CI, 0.77-0.84] vs 0.79 [95% CI, 0.77-0.82]) and clinical scenarios (eg, before COVID-19 era: C statistic, 0.79 [95% CI, 0.77-0.81]) with good and stable performance. Conclusions and Relevance: In this study, an accurate prediction model for mortality among kidney recipients, computable at the time of transplant, was developed and externally validated. Results suggest that this model may help stratify patient risk of death, allowing for improved medical decisions.

Indexed as

Kidney TransplantationTransplant RecipientsAdultCohort StudiesEuropeFemaleFranceHumansMaleMiddle AgedPrognosisProspective StudiesRisk AssessmentRisk Factors

Identifiers

PMID42024384
PMCPMC13107225

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.